FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:801-806 September 9, 1999 Number 11 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Point mutations in the factor V gene (factor V Leiden) and the prothrombin gene (the substitution of A for G at position 20210) are the most common causes of inherited thrombophilia. Whether or not factor V Leiden increases the risk of recurrent deep venous thrombosis is controversial, and there is no information on the risk of recurrence among carriers of both mutations.

Methods We studied a retrospective cohort of 624 patients who were referred for a first episode of deep venous thrombosis. After excluding 212 patients with other inherited or acquired causes of thrombophilia, we compared 112 patients who were heterozygous carriers of factor V Leiden with 17 patients who were heterozygous for both factor V Leiden and the prothrombin mutation and 283 patients who had neither mutation. The relative risk of recurrent deep venous thrombosis was calculated with use of a proportional-hazards model.

Results Patients who were heterozygous for factor V Leiden alone had a risk of recurrent deep venous thrombosis that was similar to that among patients who had neither mutation (relative risk, 1.1; 95 percent confidence interval, 0.7 to 1.6; P=0.76). In contrast, patients who were heterozygous for both factor V Leiden and the prothrombin mutation had a higher risk of recurrent thrombosis than did carriers of factor V Leiden alone (relative risk, 2.6; 95 percent confidence interval, 1.3 to 5.1; P=0.002). When the analysis was restricted to patients with spontaneous recurrences (i.e., ones that occurred in the absence of transient risk factors for venous thrombosis), the risk among carriers of both mutations, as compared with carriers of factor V Leiden alone, remained high (relative risk, 3.7; 95 percent confidence interval, 1.7 to 7.7; P<0.001), particularly if the first event had also been spontaneous (relative risk, 5.4; 95 percent confidence interval, 2.0 to 14.1; P<0.001). In contrast, the risk of recurrence in the presence of transient risk factors was similar among carriers of both mutations and carriers of factor V Leiden alone.

Conclusions The risk of recurrent deep venous thrombosis is similar among carriers of factor V Leiden and patients without this mutation. Carriers of both factor V Leiden and the G20210A prothrombin mutation have an increased risk of recurrent deep venous thrombosis after a first episode and are candidates for lifelong anticoagulation.

Source Information

From the Department of Hematology, Catholic University, Rome (V.D., K.P., P.C., I.C., E.R., G.L.), and the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Maggiore, University of Milan, Milan (I.M., P.M.M.) — both in Italy.

Address reprint requests to Dr. De Stefano at the Istituto Semeiotica Medica, Università Cattolica, Largo Gemelli 8, 00168 Rome, Italy.

Full Text of this Article

Related Letters:

The Risk of Recurrent Deep Venous Thrombosis
van der Heijden J. F., Kraaijenhagen R. A., Büller H. R., De Stefano V., Martinelli I., Leone G., Mannucci P. M.
Extract | Full Text  
N Engl J Med 2000; 342:214-215, Jan 20, 2000. Correspondence

This article has been cited by other articles:

• Ferguson, J. L., Hennion, D. R. (2008). Portal Vein Thrombosis: An Unexpected Finding in a 28-Year-Old Male With Abdominal Pain. J Am Board Fam Med 21: 237-243 [Abstract] [Full Text]  
• Prandoni, P., Noventa, F., Ghirarduzzi, A., Pengo, V., Bernardi, E., Pesavento, R., Iotti, M., Tormene, D., Simioni, P., Pagnan, A. (2007). The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. haematol 92: 199-205 [Abstract] [Full Text]  
• Zheng, X., Li, W., Gu, J.-M., Qu, D., Ferrell, G. L., Esmon, N. L., Esmon, C. T. (2007). Effects of membrane and soluble EPCR on the hemostatic balance and endotoxemia in mice. Blood 109: 1003-1009 [Abstract] [Full Text]  
• Scarvelis, D., Wells, P. S. (2006). Diagnosis and treatment of deep-vein thrombosis.. CMAJ 175: 1087-1092 [Abstract] [Full Text]  
• Ho, W. K., Hankey, G. J., Quinlan, D. J., Eikelboom, J. W. (2006). Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.. Arch Intern Med 166: 729-736 [Abstract] [Full Text]  
• Vossen, C. Y., Walker, I. D., Svensson, P., Souto, J. C., Scharrer, I., Preston, F. E., Palareti, G., Pabinger, I., van der Meer, F. J.M., Makris, M., Fontcuberta, J., Conard, J., Rosendaal, F. R. (2005). Recurrence Rate After a First Venous Thrombosis in Patients With Familial Thrombophilia. Arterioscler. Thromb. Vasc. Bio. 25: 1992-1997 [Abstract] [Full Text]  
• Davis, C. L., Delmonico, F. L. (2005). Living-Donor Kidney Transplantation: A Review of the Current Practices for the Live Donor. J. Am. Soc. Nephrol. 16: 2098-2110 [Abstract] [Full Text]  
• Christiansen, S. C., Cannegieter, S. C., Koster, T., Vandenbroucke, J. P., Rosendaal, F. R. (2005). Thrombophilia, Clinical Factors, and Recurrent Venous Thrombotic Events. JAMA 293: 2352-2361 [Abstract] [Full Text]  
• Nojima, J., Kuratsune, H., Suehisa, E., Iwatani, Y., Kanakura, Y. (2005). Acquired Activated Protein C Resistance Associated with IgG Antibodies against {beta}2-Glycoprotein I and Prothrombin as a Strong Risk Factor for Venous Thromboembolism. Clin. Chem. 51: 545-552 [Abstract] [Full Text]  
• Bank, I., Libourel, E. J., Middeldorp, S., van Pampus, E. C. M., Koopman, M. M. W., Hamulyak, K., Prins, M. H., van der Meer, J., Buller, H. R. (2004). Prothrombin 20210A Mutation: A Mild Risk Factor for Venous Thromboembolism but Not for Arterial Thrombotic Disease and Pregnancy-Related Complications in a Family Study. Arch Intern Med 164: 1932-1937 [Abstract] [Full Text]  
• Buller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., Raskob, G. E. (2004). Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 401S-428S [Abstract] [Full Text]  
• Kearon, C. (2004). Long-Term Management of Patients After Venous Thromboembolism. Circulation 110: I-10-I-18 [Abstract] [Full Text]  
• Eichinger, S., Schonauer, V., Weltermann, A., Minar, E., Bialonczyk, C., Hirschl, M., Schneider, B., Quehenberger, P., Kyrle, P. A. (2004). Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 103: 3773-3776 [Abstract] [Full Text]  
• Humphries, S. E., Ridker, P. M., Talmud, P. J. (2004). Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation?. Arterioscler. Thromb. Vasc. Bio. 24: 628-636 [Abstract] [Full Text]  
• Caprini, J. A., Glase, C. J., Anderson, C. B., Hathaway, K. (2004). Laboratory Markers in the Diagnosis of Venous Thromboembolism. Circulation 109: I-4-I-8 [Abstract] [Full Text]  
• von Ahsen, N., Oellerich, M. (2004). The intronic prothrombin 19911A>G polymorphism influences splicing efficiency and modulates effects of the 20210G>A polymorphism on mRNA amount and expression in a stable reporter gene assay system. Blood 103: 586-593 [Abstract] [Full Text]  
• McBane, R. D. II (2003). Genetically Determined Procoagulant States and Heparin Use. SEMIN CARDIOTHORAC VASC ANESTH 7: 427-442 [Abstract]  
• Frazee, L. A, Chomo, D. L (2003). Duration of Anticoagulant Therapy After Initial Idiopathic Venous Thromboembolism. The Annals of Pharmacotherapy 37: 1489-1496 [Abstract] [Full Text]  
• Heit, J. A. (2003). The Potential Role of Direct Thrombin Inhibitors in the Prevention and Treatment of Venous Thromboembolism. Chest 124: 40S-48S [Abstract] [Full Text]  
• Eichinger, S., Minar, E., Bialonczyk, C., Hirschl, M., Quehenberger, P., Schneider, B., Weltermann, A., Wagner, O., Kyrle, P. A. (2003). D-Dimer Levels and Risk of Recurrent Venous Thromboembolism. JAMA 290: 1071-1074 [Abstract] [Full Text]  
• Schulman, S. (2003). Care of Patients Receiving Long-Term Anticoagulant Therapy. NEJM 349: 675-683 [Full Text]  
• Palareti, G., Legnani, C., Cosmi, B., Valdre, L., Lunghi, B., Bernardi, F., Coccheri, S. (2003). Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia. Circulation 108: 313-318 [Abstract] [Full Text]  
• Anderson, F. A. Jr., Spencer, F. A. (2003). Risk Factors for Venous Thromboembolism. Circulation 107: I-9-16 [Abstract] [Full Text]  
• Erali, M., Schmidt, B., Lyon, E., Wittwer, C. (2003). Evaluation of Electronic Microarrays for Genotyping Factor V, Factor II, and MTHFR. Clin. Chem. 49: 732-739 [Abstract] [Full Text]  
• Ridker, P. M, Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., Paulson, R., Wong, T., Bauer, K. A., Schwartz, B. A., Miletich, J. P., Bounameaux, H., Glynn, R. J., the PREVENT Investigators, (2003). Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. NEJM 348: 1425-1434 [Abstract] [Full Text]  
• Eckman, M. H., Erban, J. K., Singh, S. K., Kao, G. S. (2003). Screening for the Risk for Bleeding or Thrombosis. ANN INTERN MED 138: W-15-W-24 [Abstract] [Full Text]  
• Deitcher, S. R, Gomes, M. P. (2003). Hypercoagulable state testing and malignancy screening following venous thromboembolic events. Vasc Med 8: 33-46 [Abstract]  
• Crowther, M. A., Kelton, J. G. (2003). Congenital Thrombophilic States Associated with Venous Thrombosis: A Qualitative Overview and Proposed Classification System. ANN INTERN MED 138: 128-134 [Abstract] [Full Text]  
• Schafer, A. I., Levine, M. N., Konkle, B. A., Kearon, C. (2003). Thrombotic Disorders: Diagnosis and Treatment. ASH Education Book 2003: 520-539 [Abstract] [Full Text]  
• Eichinger, S., Weltermann, A., Mannhalter, C., Minar, E., Bialonczyk, C., Hirschl, M., Schonauer, V., Lechner, K., Kyrle, P. A. (2002). The Risk of Recurrent Venous Thromboembolism in Heterozygous Carriers of Factor V Leiden and a First Spontaneous Venous Thromboembolism. Arch Intern Med 162: 2357-2360 [Abstract] [Full Text]  
• Evans, J. G., Lee-Tataseo, C. (2002). Determination of the Factor V Leiden Single-Nucleotide Polymorphism in a Commercial Clinical Laboratory by Use of NanoChip Microelectronic Array Technology. Clin. Chem. 48: 1406-1411 [Abstract] [Full Text]  
• Burke, W., Atkins, D., Gwinn, M., Guttmacher, A., Haddow, J., Lau, J., Palomaki, G., Press, N., Richards, C. S., Wideroff, L., Wiesner, G. L. (2002). Genetic Test Evaluation: Information Needs of Clinicians, Policy Makers, and the Public. Am J Epidemiol 156: 311-318 [Abstract] [Full Text]  
• Joffe, H. V, Goldhaber, S. Z (2002). Laboratory thrombophilias and venous thromboembolism. Vasc Med 7: 93-102 [Abstract]  
• Rosendaal, F.R., Helmerhorst, F.M., Vandenbroucke, J.P. (2002). Female Hormones and Thrombosis. Arterioscler. Thromb. Vasc. Bio. 22: 201-210 [Abstract] [Full Text]  
• Bauer, K. A., Rosendaal, F. R., Heit, J. A. (2002). Hypercoagulability: Too Many Tests, Too Much Conflicting Data. ASH Education Book 2002: 353-368 [Abstract] [Full Text]  
• Herrington, D. M., Klein, K. P. (2001). Genome and Hormones: Gender Differences in Physiology: Invited Review: Pharmacogenetics of estrogen replacement therapy. J. Appl. Physiol. 91: 2776-2784 [Abstract] [Full Text]  
• Thomas, R. H. (2001). Hypercoagulability Syndromes. Arch Intern Med 161: 2433-2439 [Abstract] [Full Text]  
• Bauer, K. A. (2001). The Thrombophilias: Well-Defined Risk Factors with Uncertain Therapeutic Implications. ANN INTERN MED 135: 367-373 [Abstract] [Full Text]  
• Mira, Y., Todoli, J., Alonso, R., Mico, M. L., Vaya, A., Ferrando, F., Estelles, A., Villa, P., Aznar, J. (2001). Factor V Leiden and Prothrombin G20210A in Relation to Arterial and/or Vein Rethrombosis: Two Cases. CLIN APPL THROMB HEMOST 7: 234-237 [Abstract]  
• Marchetti, M., Quaglini, S., Barosi, G. (2001). Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. QJM 94: 365-372 [Abstract] [Full Text]  
• CHAK, M, WALLACE, G R, GRAHAM, E M, STANFORD, M R (2001). Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease. Br. J. Ophthalmol. 85: 883-886 [Full Text]  
• Federman, D. G., Kirsner, R. S. (2001). An Update on Hypercoagulable Disorders. Arch Intern Med 161: 1051-1056 [Abstract] [Full Text]  
• Seligsohn, U., Lubetsky, A. (2001). Genetic Susceptibility to Venous Thrombosis. NEJM 344: 1222-1231 [Full Text]  
• Nowak-Gottl, U., Junker, R., Kreuz, W., von Eckardstein, A., Kosch, A., Nohe, N., Schobess, R., Ehrenforth, S. (2001). Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 97: 858-862 [Abstract] [Full Text]  
• Vaya, A., Todoli, J., Ricart, J., Estelles, A., Mira, Y., Villa, P., Calabuig, J. R., Aznar, J. (2001). Upper Extremity Deep Vein Thrombosis in a Young Patient Double Heterozygous for Factor V Leiden and Prothrombin G20210A Mutation. CLIN APPL THROMB HEMOST 7: 72-74 [Abstract]  
• Miles, J. S., Miletich, J. P., Goldhaber, S. Z., Hennekens, C. H., Ridker, P. M. (2001). G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 37: 215-218 [Abstract] [Full Text]  
• Cui, J., Eitzman, D. T., Westrick, R. J., Christie, P. D., Xu, Z. J., Yang, A. Y., Purkayastha, A. A., Yang, T. L., Metz, A. L., Gallagher, K. P., Tyson, J. A., Rosenberg, R. D., Ginsburg, D. (2000). Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 96: 4222-4226 [Abstract] [Full Text]  
• Douketis, J. D., Foster, G. A., Crowther, M. A., Prins, M. H., Ginsberg, J. S. (2000). Clinical Risk Factors and Timing of Recurrent Venous Thromboembolism During the Initial 3 Months of Anticoagulant Therapy. Arch Intern Med 160: 3431-3436 [Abstract] [Full Text]  
• Sykes, T C F, Fegan, C, Mosquera, D (2000). Thrombophilia, polymorphisms, and vascular disease. Mol. Pathol. 53: 300-306 [Abstract] [Full Text]  
• Simioni, P., Prandoni, P., Lensing, A. W. A., Manfrin, D., Tormene, D., Gavasso, S., Girolami, B., Sardella, C., Prins, M., Girolami, A. (2000). Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 96: 3329-3333 [Abstract] [Full Text]  
• Solymoss, S. (2000). Risk factors for thromboembolism: pathophysiology and detection. CMAJ 163: 991-994 [Full Text]  
• Kyrle, P. A., Minar, E., Hirschl, M., Bialonczyk, C., Stain, M., Schneider, B., Weltermann, A., Speiser, W., Lechner, K., Eichinger, S. (2000). High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism. NEJM 343: 457-462 [Abstract] [Full Text]  
• Castoldi, E., Simioni, P., Kalafatis, M., Lunghi, B., Tormene, D., Girelli, D., Girolami, A., Bernardi, F. (2000). Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family. Blood 96: 1443-1448 [Abstract] [Full Text]  
• Madonna, P., De Stefano, V., Coppola, A., Albisinni, R., Cerbone, A. M. (2000). G20210A PRTH Gene Mutation and Other Trombophilic Polymorphisms in Patients With Cerebral Vein Thrombosis. Stroke 31 : 1785-1790 [Full Text]  
• Nguyen, A. (2000). State-of-the-Art Review : Review and Management of Patients With the Prothrombin G20210A Polymorphism. CLIN APPL THROMB HEMOST 6: 94-99 [Abstract]  
• Lane, D. A., Grant, P. J. (2000). Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 95: 1517-1532 [Full Text]  
• van der Heijden, J. F., Kraaijenhagen, R. A., Buller, H. R., De Stefano, V., Martinelli, I., Leone, G., Mannucci, P. M. (2000). The Risk of Recurrent Deep Venous Thrombosis. NEJM 342: 214-215 [Full Text]  
• Topol, E. J., McCarthy, J., Gabriel, S., Moliterno, D. J., Rogers, W. J., Newby, L. K., Freedman, M., Metivier, J., Cannata, R., O'Donnell, C. J., Kottke-Marchant, K., Murugesan, G., Plow, E. F., Stenina, O., Daley, G. Q. (2001). Single Nucleotide Polymorphisms in Multiple Novel Thrombospondin Genes May Be Associated With Familial Premature Myocardial Infarction. Circulation 104: 2641-2644 [Abstract] [Full Text]  
• Eitzman, D. T., Westrick, R. J., Bi, X., Manning, S. L., Wilkinson, J. E., Broze, G. J., Ginsburg, D. (2002). Lethal Perinatal Thrombosis in Mice Resulting From the Interaction of Tissue Factor Pathway Inhibitor Deficiency and Factor V Leiden. Circulation 105: 2139-2142 [Abstract] [Full Text]